21:54 , Oct 31, 2018 |  BC Extra  |  Company News

GSK cuts some respiratory targets, keeps others in play

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) cut three respiratory programs against targets largely ignored by the rest of the industry after all three failed to meet efficacy targets in Phase II trials. The pharma disclosed the pruning...
16:54 , May 25, 2017 |  BC Innovations  |  Translation in Brief

Neutralizing neutrophils

Scientists at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) uncovered a new role for a known kinase in neutrophil activation and blocked the protein to treat inflammatory diseases. Pathway data suggest targeting the kinase...
19:39 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In a mouse model of PDAC, CXCR2 knockout decreased tumor growth and the number of tumor-infiltrating neutrophils and increased survival...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); programmed cell death 1 (PD-1; PDCD1; CD279)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In patient samples, high levels of CXCR2 in neutrophils at the tumor borders correlated with disease...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); chemokine CXC motif ligand 5 (CXCL5; ENA78)

Cancer INDICATION: Prostate cancer Mouse and cell culture studies suggest CXCR2 inhibitors could help treat invasive prostate cancer. In a mouse model of highly invasive prostate cancer, tumor levels of CXCL5 and CXCR2-expressing myeloid-derived suppressor...